Press ReleasesView printer-friendly version << Back
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
|Webcast:||A live and archived webcast of the presentation will be available at (click here) or on the Company’s website (click here)|
In addition, management will be participating in one-on-one meetings with investors who are registered to attend the conference.
About Avadel Pharmaceuticals plc:
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. The Company recently completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.
Chief Financial Officer
Phone: (636) 449-1843
Phone: (212) 915-2564
Phone: (646) 970-4688
Source: Avadel Pharmaceuticals plc